AACR 2022

Characterization of Sub-Clonal RAS/BRAF Alterations in an Anti-EGFR Treated Advanced CRC Cohort using a Liquid Biopsy-Based Real World Clinical Genomics Database

Abubaker | Poster #5245

Peposertib-Induced Senescence Primes Irradiated p53 Wild-Type Cancer Cells for Clearance by both Immune Cells and Senolytic Drugs

Carr | Poster #208

A Novel Computational Framework Predicts Synthetic Lethal Interactions between Key Regulators of DNA Damage Response and Chromatin Modifiers

Coenen-Stass | Poster #876

Liquid Biopsy Based Multiomics Profiling using Low Pass Whole Genome Sequencing and Proteomics with Computational Modeling Reveals Molecular Features of Disease Severity in EGFR/ALK Wildtype NSCLC Patients

Feng | Poster #5113

Precision Oncology-Driven Real World Clinical Genomics Data Mining of METalterations, TMB, and PD-L1 to Empower Indication Agnostic Patient Enrollment and Combination Strategies

Feng | Poster #5737

Tepotinib Efficacy and Safety in Patients with MET Exon 14 (METex14) Skipping NSCLC

Garassino | Poster #CT536

Detection of MET Alterations at the DNA, RNA and Protein Levels in NSCLC Patients Progressing on ALK and ROS1 Targeted Therapies

Jordana-Ariza | Poster #1106

Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification: Final Analysis of INSIGHT

Liam | Poster #CT538

Immunohistochemistry-informed AI Systems for Improved Characterization of Tumor-Microenvironment in Clinical Non-Small Cell Lung Cancer H&E Samples

Mrowiec | Poster #457

Comparing Comprehensive NGS Panel(s) Based Approach to Tissue Whole Exome Sequencing (WES) using Matched Tissue and Circulating Tumor DNA from Late Stage Colorectal Cancer Patients.

O'Rourke | Poster #5105

Development and Validation of a Liquid Biopsy Assay with Cerebrospinal Fluid Derived Cell Free DNA using Droplet Digital PCR for Clinical Applications

O'Rourke | Poster #5110

The IAP Antagonist Xevinapant in Combination with High-Dose Cisplatin Chemoradiotherapy Induces NF-κB and Apoptotic Pathway Biomarkers in Patients with High-Risk, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Piggott | Poster #603

MET or SHP2 Inhibition Enhances Targeted Therapies and Delays the Emergence of Resistance in Oncogene-Driven NSCLC

Reischmann | Poster #1105

A first-in-human study of the dual A2A /A2B adenosine receptor antagonist M1069 in patients with advanced solid tumors

Siu | Poster #CT240

Longitudinal Evaluation of ctDNA Molecular Response for Monitoring Clinical Benefit and Investigating Treatment Related Impacts in Metastatic Colorectal Cancer Patients Treated with Different Drug Regimens

Smith | Poster #5748

Selection of the Recommended Phase 3 Dose for the IAP Antagonist Xevinapant in Combination with High-Dose Cisplatin with Concurrent Radiotherapy (CRT) in Patients with High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)

Vugmeyster | Poster #5424

Comprehensive Next Generation Sequencing Profiling in Combination with Transcriptomic based Tumor Molecular Subtyping and Harmonized TMB Calculation using Paired Specimens from Late Stage CRC Patients

Wang | Poster #5743

Characterization of Sideness related Differentiated Genetic Alterations in Stage I IV Colorectal Cancer Patients by using Whole Exome Sequencing

Wang | Poster #5744

Anti-Tumor Immunity and Efficacy of Combination Treatment of M6223 and Bintrafusp Alfa Versus the Combination of M6223 and Anti–PD-L1 in Preclinical Tumor Models

Xu | Poster #593

M1069 as Dual A RESULTS 2A/ A2B Adenosine Receptor Antagonist Counteracts Immune-Suppressive Mechanisms of Adenosine and Reduces Tumor Growth In Vivo

Zaynagetdinov | Poster #3499

M1774, a Novel Potent and Selective ATR Inhibitor, Shows Antitumor Effects as Monotherapy and in Combination

Zimmermann | Poster #2588

Translational PK/PD/Efficacy Modelling and Efficacious Human Dose Prediction for a First in Class MUC1xEGFR (M1231) Bispecific Antibody Drug Conjugate

Zutshi | Poster #5423